in this issue of Neuron reveal that weak base antipsychotic drugs inhibit presynaptic function in an activity-dependent manner via their release from synaptic vesicles.
The treatment of schizophrenia has relied heavily on antipsychotic drugs (APDs) that primarily impact on the dopaminergic system, principally at D2 receptors (Strange, 2001) . APDs act with high affinity (in the low nanomolar range) with clinical efficacy closely matching their published potency at D2 receptors (Strange, 2001) . However, some aspects of APD action are difficult to explain based solely on their action at D2 receptors. For example, the therapeutic benefit of APDs increases slowly during treatment, an occurrence which correlates with their accumulation in tissue (Agid et al., 2003) . APDs also inhibit voltage-gated sodium (Ogata and Narahashi, 1989) and calcium channels (Sah and Bean, 1994) , implicating them in the control of neurotransmitter release. However, the clinical relevance of this potential presynaptic mechanism of action was largely dismissed, since it requires micromolar concentrations of APDs.
It has been known for years that APDs such as clozapine and haloperidol exhibit increased accumulation in brain (Strange, 2001) . This phenomenon has been ascribed to the fact that many APDs are weak bases, allowing them to accumulate in acidic intracellular compartments such as endosomes or synaptic vesicles (SVs) (Rayport and Sulzer, 1995) . This enrichment suggests that accumulation of weak-base APDs in SVs could create a highly concentrated reservoir of drug for release during synaptic activity. In this issue of Neuron, Tischbirek et al. (2012) reveal that APDs are released during SV fusion at concentrations sufficient to inhibit presynaptic voltage-gated sodium channels. This results in reduced presynaptic calcium influx, which limits subsequent SV exocytosis and neurotransmitter release (Figure 1) . Therefore, in addition to established high affinity effects on dopaminergic receptors by the free circulating drug, Tischbirek et al. (2012) describe a novel lower-affinity, use-dependent effect at voltage-gated sodium channels that only manifests during evoked neurotransmitter release.
To demonstrate vesicular accumulation of APDs, the fluorescent reporter lysotracker red (LTR) was used as a mimic of drug behavior. LTR is also a weak base, and was shown to accumulate in SVs by either colocalization with presynaptic markers or photoconversion followed by ultrastructural analysis (Tischbirek et al., 2012) . Importantly Tischbirek and colleagues also demonstrated that LTR was released on stimulation with a train of action potentials, indicating that the dye (and by extension APDs) could be released by SV exocytosis.
Parallel mathematical modeling studies predicted that APDs would be accumulated inside SVs in the micromolar range. Therefore, Tischbirek et al. (2012) next questioned whether acute application of such concentrations of APDs modulated presynaptic function. The effects of four APDs were assessed (haloperidol, chlorpromazine, clozapine, and risperidone). SV exocytosis was monitored using the pH-sensitive fluorescent genetic reporter synaptopHluorin (Sankaranarayanan and Ryan, 2000) and calcium influx measured using the fluorescent dye fluo-4. In all cases, acute application of APDs inhibited both calcium influx and SV exocytosis evoked by action potential stimulation in a dose-dependent manner. Both effects were due to an upstream inhibition of voltage-gated sodium channels, since acute APD application had no effect on SV exocytosis elicited by KCl, a stimulus that bypasses these channels.
This observed inhibition of presynaptic function by APDs can only be physiologically relevant if the drugs were (1) concentrated inside SVs and (2) released on neuronal stimulation. To test this, Tischbirek et al. (2012) applied APDs to cultured neurons which had previously accumulated LTR. This resulted in displacement of LTR, providing indirect evidence that APDs were accumulating in SVs. Unfortunately, APD enrichment inside SVs was not directly confirmed (by using fluorescent-labeled APDs for example; Rayport and Sulzer, 1995) . Therefore, a direct estimate of the intravesicular concentration of APDs could not be determined. Importantly, however, APDs were shown to be released on neuronal stimulation in vivo, in experiments performed using animals treated with clinically relevant doses of haloperidol. In these experiments, a challenge with a depolarizing pulse raised extracellular levels of haloperidol in parallel with classical neurotransmitters such as dopamine. This result was consistent with APDs being accumulated inside SVs and then released in response to stimulation.
The most important aspect of the work was the demonstration of the functional consequences of vesicular delivery of APDs on neurotransmitter release. Tischbirek et al. (2012) showed that cultured neurons previously treated with APDs displayed a form of presynaptic autoinhibition. Key experiments revealed that during relatively mild stimulation, neurons previously exposed to APDs displayed a small reduction in the extent of SV exocytosis. However, this inhibition was much larger when cultures were challenged with higher stimulation intensities.
This phenomenon was also observed in intact slices, where glutamatergic neurotransmission in the hippocampus was inhibited in a use-dependent manner. Intriguingly these use-dependent effects were accentuated in the nucleus accumbens, which has a high concentration of dopaminergic innervation, suggesting a region-, or potentially circuit-specific bias of inhibition. In this context, it will be critical for future studies to determine whether the vesicular delivery of APDs disproportionately impacts on key circuits and receptor systems implicated in schizophrenia (Lisman et al., 2008) .
The results described above suggested that neurotransmitter release was being inhibited by APDs that were released during SV fusion. This was confirmed in elegant experiments where the vesicular pH gradient was collapsed using the V-ATPase inhibitor folimycin in neuronal culture. Inhibition of the V-ATPase removed the driving force for APD accumulation into SVs, and thus depleted the vesicular reservoir of drug. Folimycin treatment resulted in a partial reversal of the APD-dependent inhibition of both SV exocytosis and calcium influx, confirming the vesicular nature of APD release.
By integrating single-cell fluorescence imaging approaches and in vitro and in vivo physiology, Tischbirek et al. (2012) have revealed a novel delivery mechanism for APDs that may contribute to their medicinal action. Unsurprisingly this work highlights areas for future study. The first is the observed lack of effect on the SV pH gradient by APD accumulation. Most weak bases that accumulate into acidic compartments become protonated and thus either collapse or reduce the pH gradient (Cousin and Nicholls, 1997) . However, this does not occur with weak base APDs, even at predicted micromolar concentrations. This is an important point, since an increase in pH will reduce neurotransmitter uptake into SVs. A potential explanation for this observed absence of effect is that vesicular pH was monitored using the genetic reporter synaptopHluorin. A significant percentage of synaptopHluorin is expressed at the plasma membrane in culture (Sankaranarayanan and Ryan, 2000) (where it is fluorescent) meaning the potential dynamic range for monitoring increases in SV pH (and fluorescence) will be small. In support, collapse of the vesicular pH gradient using folimycin only increased synaptopHluorin fluorescence by 50% (Tischbirek et al., 2012) . Similarly, the displacement of LTR by APDs was taken as evidence of drug accumulation in SVs. However it is unclear why LTR would be displaced if the pH gradient is unaffected. One future test to confirm that APDs have no effect on neurotransmitter uptake into SVs would be to utilize recently developed fluorescent false neurotransmitters (Gubernator et al., 2009 ) to determine any modulation of their uptake and release by these drugs during KCl-evoked SV turnover.
The central hypothesis of the work outlined by Tischbirek et al. (2012) is that APDs are released during SV fusion to inhibit presynaptic sodium channels. However, do APDs remain in the synaptic cleft at micromolar concentrations for a sufficient time to exert their effect? Glutamate is stored in SVs at high millimolar levels. Extensive modeling studies have revealed that released glutamate only remains at such concentrations within 100 nm of the release site and even then dissipates to micromolar levels within less than 100 microseconds, a dilution of approximately 100-fold (Diamond and Jahr, 1997; Raghavachari and Lisman, 2004) . If these parameters were recapitulated for APDs, it would confound their proposed mechanism of action, since drug would be diluted below its IC 50 for channel antagonism. However, glutamate is a charged, hydrophilic molecule whose synaptic concentration is controlled by both diffusion and reuptake by transport proteins, whereas APDs are lipophilic molecules with no known transport targets. These factors may retard the exit of APDs from the tight, membrane-delimited synaptic cleft. Importantly, Tischbirek et al. (2012) also demonstrated that sodium channels are inhibited by APDs with far greater potency (two orders of magnitude) when they are in their inactivated state, suggesting they may exert a biological effect even after their dilution in the cleft. It will therefore be critical for future studies to determine the APD concentration in the synapse, while considering the clinically relevant circulating free concentration of drug.
Finally this study reiterates the extraordinary fact that SVs recycle perfectly well with an altered luminal cargo or indeed no cargo at all (Cousin and Nicholls, 1997) . The demonstration by Tischbirek et al. (2012) that key psychoactive drugs are accumulated inside SVs and delivered with high precision provides a potentially useful strategy for designing compounds with an activity-dependent mode of action. By altering the pKa of lead compounds, novel drugs could be designed that are accumulated inside SVs. Vesicular accumulation would have no obvious effects on presynaptic function per se but could be potentially highly effective in targeting therapies to a range of mental health disorders and neurodegenerative conditions where synaptic dysfunction is a critical early step in disease progression (Bear et al., 2004 ; Circulating nanomolar concentrations of weak base antipsychotic drugs (APDs) are sufficient to exert effects at high affinity sites (D2 receptors) but insufficient to impact on other lower affinity targets (sodium channels) in resting neurons. APDs accumulate in SVs at micromolar concentrations. Upon SV exocytosis (activity), APDs are released into the synaptic cleft, where they can exert an autoinhibitory action on presynaptic function by inhibiting sodium channels and thus downstream calcium influx and neurotransmitter release.
